Loading organizations...

§ Venture Capital · San Mateo, CA, USA
Venture capital firm investing in exit-ready technology companies, focused on accelerating tech firms in cybersecurity, AI, and software.
Aethan Capital operates as an investment firm, systematically building a specialized portfolio within healthcare and life sciences. The firm focuses capital on companies advancing drug discovery and developing therapeutic devices. Its strategy involves providing financial backing to accelerate development and commercialization of innovative medical technologies, cultivating assets in critical health areas.
Founders and specific origin details for Aethan Capital are not publicly available through standard corporate disclosures. The firm established itself as a financial entity committed to strategic investments within specialized healthcare segments. Consistent investment activity reflects a foundational purpose centered on capitalizing on growth from medical innovation.
Aethan Capital primarily partners with early to growth-stage companies innovating in drug discovery and medical devices, serving as a vital capital provider. Its vision centers on catalyzing innovation within these high-potential sectors, aiming to accelerate technologies capable of improving patient care. Targeted investments facilitate the market entry of groundbreaking healthcare solutions.
Aethan Capital has 2 tracked investments across 2 companies. The latest tracked deal is $64.0M Series B in SetPoint Medical in January 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 1, 2021 | SetPoint Medical | $64.0M Series B | Josh Makower | Action Potential Venture Capital, Morgenthaler Ventures, NEW Enterprise Associates (NEA), Norwest Venture Partners, Runway Growth Capital, ShangBay Capital, Asahi Kasei, Ascendum Capital, Banyan Pacific Capital, Boston Scientific, Catalio Capital, Citta Capital, Euclidean Capital, Midas Capital, Morgenthaler Ventures, Revelation Partners, Richard King Mellon Foundation, SVE Capital, Topspin Fund |
| Jun 1, 2019 | Corinth MedTech | $12.0M Series D | ShangBay Capital, Aethan Capital | — |